The global Biosimilars & Follow-on-Biologics market is projected to reach US$ 52070 million in 2029, increasing from US$ 22490 million in 2022, with the CAGR of 15.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Biosimilars & Follow-on-Biologics market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Biosimilars & Follow-on-Biologics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis
Synthon Pharmaceuticals
Teva Pharmaceutical Industries
LG Life Sciences
Celltrion
Biocon
Hospira
Merck Group
Biogen idec, Inc.
Genentech (Roche Group)
Segment by Type
Human Growth Hormone
Erythropoietin
Monoclonal Antibodies
Insulin
Interferon
Granulocyte-Colony Stimulating Factor
Peptide
Others
Segment by Application
Blood Disorders
Oncology Diseases
Chronic and Autoimmune Diseases
Growth Hormone Deficiencies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Biosimilars & Follow-on-Biologics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biosimilars & Follow-on-Biologics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Human Growth Hormone
1.2.3 Erythropoietin
1.2.4 Monoclonal Antibodies
1.2.5 Insulin
1.2.6 Interferon
1.2.7 Granulocyte-Colony Stimulating Factor
1.2.8 Peptide
1.2.9 Others
1.3 Market by Application
1.3.1 Global Biosimilars & Follow-on-Biologics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Blood Disorders
1.3.3 Oncology Diseases
1.3.4 Chronic and Autoimmune Diseases
1.3.5 Growth Hormone Deficiencies
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biosimilars & Follow-on-Biologics Market Perspective (2018-2029)
2.2 Biosimilars & Follow-on-Biologics Growth Trends by Region
2.2.1 Global Biosimilars & Follow-on-Biologics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Biosimilars & Follow-on-Biologics Historic Market Size by Region (2018-2023)
2.2.3 Biosimilars & Follow-on-Biologics Forecasted Market Size by Region (2024-2029)
2.3 Biosimilars & Follow-on-Biologics Market Dynamics
2.3.1 Biosimilars & Follow-on-Biologics Industry Trends
2.3.2 Biosimilars & Follow-on-Biologics Market Drivers
2.3.3 Biosimilars & Follow-on-Biologics Market Challenges
2.3.4 Biosimilars & Follow-on-Biologics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biosimilars & Follow-on-Biologics Players by Revenue
3.1.1 Global Top Biosimilars & Follow-on-Biologics Players by Revenue (2018-2023)
3.1.2 Global Biosimilars & Follow-on-Biologics Revenue Market Share by Players (2018-2023)
3.2 Global Biosimilars & Follow-on-Biologics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Biosimilars & Follow-on-Biologics Revenue
3.4 Global Biosimilars & Follow-on-Biologics Market Concentration Ratio
3.4.1 Global Biosimilars & Follow-on-Biologics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosimilars & Follow-on-Biologics Revenue in 2022
3.5 Biosimilars & Follow-on-Biologics Key Players Head office and Area Served
3.6 Key Players Biosimilars & Follow-on-Biologics Product Solution and Service
3.7 Date of Enter into Biosimilars & Follow-on-Biologics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Biosimilars & Follow-on-Biologics Breakdown Data by Type
4.1 Global Biosimilars & Follow-on-Biologics Historic Market Size by Type (2018-2023)
4.2 Global Biosimilars & Follow-on-Biologics Forecasted Market Size by Type (2024-2029)
5 Biosimilars & Follow-on-Biologics Breakdown Data by Application
5.1 Global Biosimilars & Follow-on-Biologics Historic Market Size by Application (2018-2023)
5.2 Global Biosimilars & Follow-on-Biologics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Biosimilars & Follow-on-Biologics Market Size (2018-2029)
6.2 North America Biosimilars & Follow-on-Biologics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Biosimilars & Follow-on-Biologics Market Size by Country (2018-2023)
6.4 North America Biosimilars & Follow-on-Biologics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biosimilars & Follow-on-Biologics Market Size (2018-2029)
7.2 Europe Biosimilars & Follow-on-Biologics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Biosimilars & Follow-on-Biologics Market Size by Country (2018-2023)
7.4 Europe Biosimilars & Follow-on-Biologics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biosimilars & Follow-on-Biologics Market Size (2018-2029)
8.2 Asia-Pacific Biosimilars & Follow-on-Biologics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Biosimilars & Follow-on-Biologics Market Size by Region (2018-2023)
8.4 Asia-Pacific Biosimilars & Follow-on-Biologics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biosimilars & Follow-on-Biologics Market Size (2018-2029)
9.2 Latin America Biosimilars & Follow-on-Biologics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Biosimilars & Follow-on-Biologics Market Size by Country (2018-2023)
9.4 Latin America Biosimilars & Follow-on-Biologics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biosimilars & Follow-on-Biologics Market Size (2018-2029)
10.2 Middle East & Africa Biosimilars & Follow-on-Biologics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Biosimilars & Follow-on-Biologics Market Size by Country (2018-2023)
10.4 Middle East & Africa Biosimilars & Follow-on-Biologics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis Biosimilars & Follow-on-Biologics Introduction
11.1.4 Novartis Revenue in Biosimilars & Follow-on-Biologics Business (2018-2023)
11.1.5 Novartis Recent Development
11.2 Synthon Pharmaceuticals
11.2.1 Synthon Pharmaceuticals Company Detail
11.2.2 Synthon Pharmaceuticals Business Overview
11.2.3 Synthon Pharmaceuticals Biosimilars & Follow-on-Biologics Introduction
11.2.4 Synthon Pharmaceuticals Revenue in Biosimilars & Follow-on-Biologics Business (2018-2023)
11.2.5 Synthon Pharmaceuticals Recent Development
11.3 Teva Pharmaceutical Industries
11.3.1 Teva Pharmaceutical Industries Company Detail
11.3.2 Teva Pharmaceutical Industries Business Overview
11.3.3 Teva Pharmaceutical Industries Biosimilars & Follow-on-Biologics Introduction
11.3.4 Teva Pharmaceutical Industries Revenue in Biosimilars & Follow-on-Biologics Business (2018-2023)
11.3.5 Teva Pharmaceutical Industries Recent Development
11.4 LG Life Sciences
11.4.1 LG Life Sciences Company Detail
11.4.2 LG Life Sciences Business Overview
11.4.3 LG Life Sciences Biosimilars & Follow-on-Biologics Introduction
11.4.4 LG Life Sciences Revenue in Biosimilars & Follow-on-Biologics Business (2018-2023)
11.4.5 LG Life Sciences Recent Development
11.5 Celltrion
11.5.1 Celltrion Company Detail
11.5.2 Celltrion Business Overview
11.5.3 Celltrion Biosimilars & Follow-on-Biologics Introduction
11.5.4 Celltrion Revenue in Biosimilars & Follow-on-Biologics Business (2018-2023)
11.5.5 Celltrion Recent Development
11.6 Biocon
11.6.1 Biocon Company Detail
11.6.2 Biocon Business Overview
11.6.3 Biocon Biosimilars & Follow-on-Biologics Introduction
11.6.4 Biocon Revenue in Biosimilars & Follow-on-Biologics Business (2018-2023)
11.6.5 Biocon Recent Development
11.7 Hospira
11.7.1 Hospira Company Detail
11.7.2 Hospira Business Overview
11.7.3 Hospira Biosimilars & Follow-on-Biologics Introduction
11.7.4 Hospira Revenue in Biosimilars & Follow-on-Biologics Business (2018-2023)
11.7.5 Hospira Recent Development
11.8 Merck Group
11.8.1 Merck Group Company Detail
11.8.2 Merck Group Business Overview
11.8.3 Merck Group Biosimilars & Follow-on-Biologics Introduction
11.8.4 Merck Group Revenue in Biosimilars & Follow-on-Biologics Business (2018-2023)
11.8.5 Merck Group Recent Development
11.9 Biogen idec, Inc.
11.9.1 Biogen idec, Inc. Company Detail
11.9.2 Biogen idec, Inc. Business Overview
11.9.3 Biogen idec, Inc. Biosimilars & Follow-on-Biologics Introduction
11.9.4 Biogen idec, Inc. Revenue in Biosimilars & Follow-on-Biologics Business (2018-2023)
11.9.5 Biogen idec, Inc. Recent Development
11.10 Genentech (Roche Group)
11.10.1 Genentech (Roche Group) Company Detail
11.10.2 Genentech (Roche Group) Business Overview
11.10.3 Genentech (Roche Group) Biosimilars & Follow-on-Biologics Introduction
11.10.4 Genentech (Roche Group) Revenue in Biosimilars & Follow-on-Biologics Business (2018-2023)
11.10.5 Genentech (Roche Group) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Novartis
Synthon Pharmaceuticals
Teva Pharmaceutical Industries
LG Life Sciences
Celltrion
Biocon
Hospira
Merck Group
Biogen idec, Inc.
Genentech (Roche Group)
*If Applicable.